WallStSmart

Nebius Group N.V. (NBIS)vsTNL Mediagene Ordinary Shares (TNMG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nebius Group N.V. generates 2628% more annual revenue ($1.36B vs $49.67M). NBIS leads profitability with a 3.1% profit margin vs -167.9%. NBIS earns a higher WallStSmart Score of 43/100 (D).

NBIS

Hold

43

out of 100

Grade: D

Growth: 8.0Profit: 3.0Value: 7.7Quality: 6.5
Piotroski: 5/9Altman Z: 1.10

TNMG

Avoid

32

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 3.0
Piotroski: 4/9Altman Z: -7.25
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NBISUndervalued (+52.2%)

Margin of Safety

+52.2%

Fair Value

$469.87

Current Price

$212.19

$257.68 discount

UndervaluedFair: $469.87Overvalued

Intrinsic value data unavailable for TNMG.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NBIS3 strengths · Avg: 9.0/10
Revenue GrowthGrowth
454.0%10/10

Revenue surging 454.0% year-over-year

Market CapQuality
$57.01B9/10

Large-cap with strong market position

PEG RatioValuation
0.538/10

Growing faster than its price suggests

TNMG1 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Areas to Watch

NBIS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.6%3/10

ROE of 0.6% — below average capital efficiency

Profit MarginProfitability
3.1%3/10

3.1% margin — thin

Free Cash FlowQuality
$-3.41B2/10

Negative free cash flow — burning cash

TNMG4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.66M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-164.6%2/10

ROE of -164.6% — below average capital efficiency

Free Cash FlowQuality
$-3.15M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : NBIS

The strongest argument for NBIS centers on Revenue Growth, Market Cap, PEG Ratio. Revenue growth of 454.0% demonstrates continued momentum. PEG of 0.53 suggests the stock is reasonably priced for its growth.

Bull Case : TNMG

The strongest argument for TNMG centers on Price/Book.

Bear Case : NBIS

The primary concerns for NBIS are EPS Growth, Return on Equity, Profit Margin. Thin 3.1% margins leave little buffer for downturns.

Bear Case : TNMG

The primary concerns for TNMG are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 23.52 is elevated, increasing financial risk.

Key Dynamics to Monitor

NBIS profiles as a hypergrowth stock while TNMG is a turnaround play — different risk/reward profiles.

NBIS carries more volatility with a beta of 1.44 — expect wider price swings.

NBIS is growing revenue faster at 454.0% — sustainability is the question.

TNMG generates stronger free cash flow (-3M), providing more financial flexibility.

Bottom Line

NBIS scores higher overall (43/100 vs 32/100) and 454.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Nebius Group N.V.

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA

Nebius Group N.V. (Ticker: NBIS) is an innovative technology firm that specializes in advanced digital solutions to enhance client engagement and operational efficiency across diverse sectors. By integrating cutting-edge cloud computing, artificial intelligence, and data analytics, Nebius enables businesses to adeptly manage the complexities of today's digital landscape. The company boasts a strong portfolio of intellectual property and strategic partnerships, positioning it favorably to capitalize on significant growth opportunities in the technology-driven marketplace. As such, Nebius presents a compelling investment opportunity for institutional investors seeking to gain exposure to pioneering solutions in the tech sector.

Visit Website →

TNL Mediagene Ordinary Shares

COMMUNICATION SERVICES · PUBLISHING · USA

TNL Mediagene Ordinary Shares is an innovative biopharmaceutical firm focused on developing and commercializing cutting-edge therapies for oncology and autoimmune disorders. The company boasts a strong pipeline driven by advanced technologies and strategic collaborations, positioning it for significant growth in the evolving healthcare market. TNL Mediagene's commitment to scientific excellence and patient-centered solutions reinforces its aim to enhance patient outcomes while addressing critical health challenges, thereby establishing itself as a notable entity within the biopharmaceutical landscape.

Visit Website →

Want to dig deeper into these stocks?